Asian shares extended gains Tuesday following a Wall Street rally, with Tokyo's Nikkei jumping more than two percent to another record following Japanese Prime Minister Sanae Takaichi's stunning ...

Speaking in front of people can make us nervous even in our first language, so it can be even worse in a foreign language ...

Live radio, text and in-play clip coverage of Saturday's seven Irish Cup sixth round fixtures ...

The Dow surged above 50,000 points for the first time Friday, shrugging off worries connected to artificial intelligence companies while traders focused on the prospects for US growth and Federal ...

Builders FirstSource (BLDR) which provides building products and manufactured components for homebuilders, contractors and ...

Markets still anticipate easing in 2026, but only at the margins. Recent reporting from Bloomberg and Reuters suggests growing interest in five-year Treasuries, reflecting concern that longer-dated ...

With long end yields elevated, fixed income remains attractive across multiple segments. Rate cuts, corporate earnings, and stable credit markets are supportive to Vanguard’s VGHY and VCIT. With the ...

For investors seeking higher yields than what intermediate core bonds can provide, the next step up the risk ladder are funds in the Morningstar intermediate core-plus bond category. To screen for the ...

You’ve moved past the rental line and are ready to buy your first pair of skis—but with so many options out there, it’s easy to feel overwhelmed. Good news: there’s no such thing as a bad ski anymore.

Large-bore mechanical thrombectomy (LBMT) was superior to catheter-directed thrombolysis (CDT) for treatment of intermediate-risk pulmonary embolism (PE), based on data from 550 individuals presented ...

Google is apparently having trouble identifying paywalled content due to a standard way paywalled content is handled by publishers like news sites. It’s asking that publishers with paywalled content ...

Irreversible electroporation using the NanoKnife System provided effective focal therapy option for intermediate-risk prostate cancer, with mostly favorable oncologic and functional outcomes. For ...